Interpace Biosciences, Inc. has announced a capital restructuring of its Preferred Stock, involving an exchange of Series B Preferred Stock for a new issuance of Series C Preferred Stock with its investors, Ampersand Capital Partners and 1315 Capital. The purpose of this restructuring is to assist the company in seeking an uplisting of its Common Stock to Nasdaq.
Company Information
Company
Interpace Biosciences
Location
Parsippany, New Jersey, United States
About
Interpace Biosciences (OTCQX: IDXG) is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
ParsippanyBiotechnologyHealthcareHealth CareGeneticsHealth Diagnostics